We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 50% below its sector, cheaper than its peers on earnings.
Level Biotechnology Inc., founded in 1989 and based in New Taipei City, Taiwan, operates in the commercialization and distribution of scientific products and services. The company supplies specialized reagents and consumables for cell culture, immunology, and molecular biology, alongside advanced biomedical instrumentation, throughout Taiwan. Beyond product distribution, Level Biotechnology offers a comprehensive suite of research and testing services. These include expert assessments in mammalian and genetic toxicology, pharmacological studies, biocompatibility testing, and the production of model animals. The firm's preclinical research capabilities serve a diverse range of clients in the biotechnology, pharmaceutical, medical device, animal health, and agrichemical industries.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 3118.TWO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
